|
US5525464A
(en)
|
1987-04-01 |
1996-06-11 |
Hyseq, Inc. |
Method of sequencing by hybridization of oligonucleotide probes
|
|
US5202231A
(en)
|
1987-04-01 |
1993-04-13 |
Drmanac Radoje T |
Method of sequencing of genomes by hybridization of oligonucleotide probes
|
|
US6054270A
(en)
|
1988-05-03 |
2000-04-25 |
Oxford Gene Technology Limited |
Analying polynucleotide sequences
|
|
US5700637A
(en)
|
1988-05-03 |
1997-12-23 |
Isis Innovation Limited |
Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
|
|
US5800992A
(en)
|
1989-06-07 |
1998-09-01 |
Fodor; Stephen P.A. |
Method of detecting nucleic acids
|
|
US5871928A
(en)
|
1989-06-07 |
1999-02-16 |
Fodor; Stephen P. A. |
Methods for nucleic acid analysis
|
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
|
US5744101A
(en)
|
1989-06-07 |
1998-04-28 |
Affymax Technologies N.V. |
Photolabile nucleoside protecting groups
|
|
DE69233501T2
(de)
|
1991-11-22 |
2006-02-23 |
Affymetrix, Inc. (n.d.Ges.d.Staates Delaware), Santa Clara |
Kombinatorische Strategien für die Polymersynthese
|
|
US5807522A
(en)
|
1994-06-17 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for fabricating microarrays of biological samples
|
|
US5795716A
(en)
|
1994-10-21 |
1998-08-18 |
Chee; Mark S. |
Computer-aided visualization and analysis system for sequence evaluation
|
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
US7928239B2
(en)
|
1999-01-13 |
2011-04-19 |
Bayer Healthcare Llc |
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
ATE538794T1
(de)
|
1999-01-13 |
2012-01-15 |
Bayer Healthcare Llc |
Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
|
|
US7351834B1
(en)
|
1999-01-13 |
2008-04-01 |
Bayer Pharmaceuticals Corporation |
ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US20020065296A1
(en)
|
1999-01-13 |
2002-05-30 |
Bayer Corporation |
Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
|
|
WO2000042012A1
(en)
|
1999-01-13 |
2000-07-20 |
Bayer Corporation |
φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
|
|
US7141581B2
(en)
|
1999-07-02 |
2006-11-28 |
Agouron Pharmaceuticals, Inc. |
Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
|
|
TWI262914B
(en)
|
1999-07-02 |
2006-10-01 |
Agouron Pharma |
Compounds and pharmaceutical compositions for inhibiting protein kinases
|
|
CZ301689B6
(cs)
|
1999-11-05 |
2010-05-26 |
Astrazeneca Ab |
Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje
|
|
EP1255536B1
(en)
|
1999-12-22 |
2006-06-28 |
Sugen, Inc. |
Indolinone derivatives for modulation of c-kit tyrosine protein kinase
|
|
SI1255752T1
(sl)
|
2000-02-15 |
2007-12-31 |
Pharmacia & Upjohn Co Llc |
S pirolom substituirani zaviralci 2-indolinon protein kinaza
|
|
EP1343782B1
(en)
|
2000-12-21 |
2009-05-06 |
SmithKline Beecham Corporation |
Pyrimidineamines as angiogenesis modulators
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
JP4982685B2
(ja)
|
2001-12-03 |
2012-07-25 |
バイエル、ファーマシューテイカルズ、コーポレイション |
ヒトがんを処置するための他の細胞毒剤又は細胞増殖抑制剤と組合わせたアリール尿素化合物
|
|
SE0104164L
(sv)
|
2001-12-11 |
2003-06-12 |
Ericsson Telefon Ab L M |
Högspännings-mos-transistor
|
|
NO317200B1
(no)
|
2002-08-09 |
2004-09-13 |
Best Practice Deployment As |
System for trafikkopplaering i et kjoretoy
|
|
CN1911962A
(zh)
|
2002-09-27 |
2007-02-14 |
奥里迪斯生物医学研究及开发有限责任公司 |
多肽与编码这些多肽的核酸和它们用于预防、诊断或治疗肝脏失调和上皮癌的用途
|
|
EP1639090A4
(en)
*
|
2003-06-09 |
2008-04-16 |
Univ Michigan |
COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
|
|
PT2213661E
(pt)
|
2003-09-26 |
2011-12-15 |
Exelixis Inc |
Moduladores de c-met e métodos de uso
|
|
GB0411378D0
(en)
|
2004-05-21 |
2004-06-23 |
Astrazeneca Ab |
Pharmaceutical compositions
|
|
EP1907858A4
(en)
*
|
2005-06-13 |
2009-04-08 |
Univ Michigan |
COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
|
|
BRPI0617488A2
(pt)
|
2005-10-21 |
2011-07-26 |
Bayer Healthcare Llc |
mÉtodo para a monitoraÇço do estado de uma doenÇa associada a uma via de vegf-165 ativada por ultra-expressço ou por mutaÇço de proteÍna vegf-165 em um paciente, mÉtodo de seleÇço de terapia para um paciente humano com uma doenÇa e mÉtodo de dignàstico para detectar uma doenÇa associada a uma via de vegf-165 ativada por ultra-expressço ou por mutaÇço de proteÍna vegf-165 em um paciente
|
|
US8329408B2
(en)
|
2005-10-31 |
2012-12-11 |
Bayer Healthcare Llc |
Methods for prognosis and monitoring cancer therapy
|
|
CA2627873A1
(en)
|
2005-10-31 |
2007-05-10 |
Scott Wilhelm |
Treatment of cancer with sorafenib
|
|
JP2009543797A
(ja)
|
2006-07-10 |
2009-12-10 |
エラン ファーマ インターナショナル，リミティド |
ナノ粒子ソラフェニブ製剤
|
|
KR20090071603A
(ko)
*
|
2006-09-19 |
2009-07-01 |
노파르티스 아게 |
Ｒａｆ 억제제에 대한 표적 조절, 효능, 진단 및/또는 예후의 바이오마커
|
|
US8609640B2
(en)
|
2007-07-25 |
2013-12-17 |
Eisai, Inc. |
Multikinase inhibitors for use in the treatment of cancer
|
|
US20090062368A1
(en)
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched sunitinib
|
|
US20090062347A1
(en)
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched axitinib
|
|
EP2195286A2
(en)
|
2007-09-10 |
2010-06-16 |
Cipla Limited |
Process for the preparation of a raf kinase inhibitor and intermediates for use in the process
|
|
EP2206775B1
(en)
*
|
2007-09-26 |
2016-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-il-6 receptor antibody
|
|
WO2009054004A2
(en)
|
2007-10-22 |
2009-04-30 |
Natco Pharma Limited |
Process for the preparation of sorafenib
|
|
EP2220071A2
(en)
|
2007-11-21 |
2010-08-25 |
Teva Pharmaceutical Industries Ltd. |
Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
|
|
US20100256392A1
(en)
|
2007-11-21 |
2010-10-07 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of sunitinib base and processes for preparation thereof
|
|
WO2009104021A2
(en)
|
2008-02-21 |
2009-08-27 |
Generics [Uk] Limited |
Novel polymorphs and processes for their preparation
|
|
WO2009106825A1
(en)
|
2008-02-27 |
2009-09-03 |
Cipla Limited |
Polymorphs of sorafenib and salts thereof
|
|
WO2009111061A1
(en)
|
2008-03-06 |
2009-09-11 |
Sicor Inc. |
Process for the preparation of sorafenib and salts thereof
|
|
EP2098521A1
(en)
|
2008-03-06 |
2009-09-09 |
Ratiopharm GmbH |
Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
|
|
CA2720164A1
(en)
|
2008-03-31 |
2009-10-08 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparing sunitinib and salts thereof
|
|
KR20110036055A
(ko)
|
2008-06-23 |
2011-04-06 |
낫코 파마 리미티드 |
고순도의 수니티닙 및 이의 약학적으로 허용가능한 염의 개선된 제조 방법
|
|
WO2010011834A2
(en)
|
2008-07-24 |
2010-01-28 |
Teva Pharmaceutical Industries Ltd. |
Sunitinib and salts thereof and their polymorphs
|
|
WO2010036796A1
(en)
|
2008-09-26 |
2010-04-01 |
Concert Pharmaceuticals, Inc. |
Pyridineamine derivatives
|
|
CA2704448A1
(en)
|
2008-09-30 |
2010-04-08 |
Teva Pharmaceutical Industries Ltd. |
Amorphous compositions of sunitinib base and l-malic acid
|
|
JP5439494B2
(ja)
*
|
2008-10-21 |
2014-03-12 |
バイエル ヘルスケア エルエルシー |
肝細胞癌と関連するシグネチャ遺伝子の同定
|
|
EP2181991A1
(en)
|
2008-10-28 |
2010-05-05 |
LEK Pharmaceuticals D.D. |
Novel salts of sunitinib
|
|
EP2186809A1
(en)
|
2008-11-13 |
2010-05-19 |
LEK Pharmaceuticals D.D. |
New crystal form of sunitinib malate
|
|
WO2010059742A1
(en)
*
|
2008-11-18 |
2010-05-27 |
Collabrx, Inc. |
Individualized cancer treatment
|
|
WO2010135608A1
(en)
*
|
2009-05-20 |
2010-11-25 |
Nodality, Inc. |
Methods for diagnosis, prognosis and methods of treatment
|
|
WO2011004200A1
(en)
|
2009-07-10 |
2011-01-13 |
Generics [Uk] Limited |
Novel pyrrole derivatives
|
|
JP2012533562A
(ja)
|
2009-07-16 |
2012-12-27 |
グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド |
治療法
|
|
US20120232102A1
(en)
|
2009-09-30 |
2012-09-13 |
Chun-Fang Xu |
Methods Of Administration And Treatment
|
|
JP2013505968A
(ja)
|
2009-10-01 |
2013-02-21 |
シーエスエル、リミテッド |
フィラデルフィア染色体陽性白血病の治療方法
|
|
US20120245051A1
(en)
*
|
2009-10-13 |
2012-09-27 |
Rimm David L |
Objective, quantitative method to predict histological subtype in non-small cell lung cancer
|
|
EP2490536A4
(en)
|
2009-10-23 |
2013-04-17 |
Glaxo Wellcome Mfg Pte Ltd |
COMPOSITION AND METHOD
|
|
TW201201808A
(en)
|
2010-01-06 |
2012-01-16 |
Glaxo Wellcome Mfg Pte Ltd |
Treatment method
|
|
WO2011100325A2
(en)
|
2010-02-09 |
2011-08-18 |
Sicor Inc. |
Polymorphs of sunitinib salts
|
|
WO2011104555A2
(en)
|
2010-02-25 |
2011-09-01 |
Generics [Uk] Limited |
Novel process
|
|
WO2011128699A2
(en)
|
2010-04-16 |
2011-10-20 |
Generics [Uk] Limited |
Novel process
|
|
TW201206908A
(en)
|
2010-05-05 |
2012-02-16 |
Glaxo Wellcome Mfg Pte Ltd |
Pharmaceutical compositions and methods of making same
|
|
WO2011146458A1
(en)
|
2010-05-18 |
2011-11-24 |
Glaxo Wellcome Manufacturing Pte Ltd |
Method of administration and treatment
|
|
WO2012058780A1
(en)
|
2010-11-01 |
2012-05-10 |
Scinopharm (Kunshan) Biochemical Technology Co., Ltd. |
Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles
|
|
US9150547B2
(en)
|
2010-11-29 |
2015-10-06 |
Hetero Research Foundation |
Process for the preparation of pazopanib using novel intermediate
|
|
WO2012088522A1
(en)
|
2010-12-23 |
2012-06-28 |
Nektar Therapeutics |
Polymer-des-ethyl sunitinib conjugates
|
|
WO2012103060A1
(en)
|
2011-01-27 |
2012-08-02 |
Glaxo Wellcome Manufacturing Pte Ltd |
Method of administration and treatment
|
|
US20120214830A1
(en)
*
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
|
CN102283836B
(zh)
|
2011-06-27 |
2013-01-09 |
苏州大学附属第一医院 |
索拉非尼在制备治疗动脉瘤性自发性蛛网膜下腔出血后发生的早期脑损伤的药物中的应用
|
|
WO2013000909A1
(en)
|
2011-06-28 |
2013-01-03 |
Bayer Intellectual Property Gmbh |
Topical ophthalmological pharmaceutical composition containing sorafenib
|
|
CN103874770A
(zh)
*
|
2011-08-08 |
2014-06-18 |
卡里斯生命科学卢森堡控股有限责任公司 |
生物标志物组合物和方法
|
|
WO2013043529A1
(en)
|
2011-09-19 |
2013-03-28 |
Emory University |
Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
|
|
WO2013046133A1
(en)
|
2011-09-30 |
2013-04-04 |
Pfizer Inc. |
Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide
|
|
US20140322166A1
(en)
*
|
2011-12-12 |
2014-10-30 |
Stc. Unm |
Gene expression signatures for detection of underlying philadelphia chromosome-like (ph-like) events and therapeutic targeting in leukemia
|
|
WO2013138522A2
(en)
*
|
2012-03-16 |
2013-09-19 |
Genelux Corporation |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
|
PT3039424T
(pt)
|
2013-08-28 |
2020-09-03 |
Crown Bioscience Inc Taicang |
Assinaturas de expressão genética que permitem prever a resposta de um sujeito a um inibidor multiquinase e métodos de utilização do mesmo
|